{"success":true,"data":{"pressRelease":{"id":"85922","rtpr_id":"nNFC9dSbb7","ticker":"DOSE","exchange":"","all_tickers":["DOSE"],"title":"Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt","author":"Newsfile Corp","published_at":"2026-07-10T23:13:31.343Z","article_body":"Burlington, Ontario--(Newsfile Corp. - July 10, 2026) - Rapid Dose\nTherapeutics Corp. (CSE: DOSE) (\"RDT\" or the \"Company\") announced today that\npursuant to the terms of its amended and restated secured convertible notes\ndated December 1, 2025 (the \"Notes\"), the Company issued common shares\n(\"Common Shares\") in satisfaction of the accrued interest payable on June 30,\n2026.\n\nThe Notes were issued as a result of an extension to the promissory notes that\nwere originally issued by the Company pursuant to its private placement\nfinancing (the \"Financing\") that closed in 2023. The Financing was an offering\nof units (the \"Units\") at a price of $1.00 per Unit. Each Unit consisted of\n$1.00 principal amount of Notes and five common share purchase warrants of the\nCompany (the \"Warrants\"). The Company closed all four tranches of the\nFinancing in 2023, issuing an aggregate of $3,134,445 principal amount of\nNotes and 15,672,225 Warrants.\n\nAs previously disclosed, the Company agreed with noteholders holding an\naggregate of $3,084,445 of promissory notes to extend the maturity date for\none year on their respective notes to November 30, 2026, and extend the expiry\ndate for one year on their accompanying 15,422,225 Warrants to November 30,\n2026. The Notes bear interest at 18% per annum, calculated and compounded\nmonthly, and added to principal and payable quarterly in arrears in Common\nShares at a price per share equal to the closing market price of the Common\nShares on the Canadian Securities Exchange (the \"CSE\") on the last trading day\nof each calendar quarter. The Company is permitted to prepay the Notes on 10\ndays' advance notice without notice or bonus.\n\nTherefore, in accordance with the terms of the Notes, the Company issued a\ntotal of 1,338,091 Common Shares to the holders of the Notes at a deemed issue\nprice of $0.105 per Common Share, being the closing market price of the Common\nShares on the CSE on June 30, 2026 (the last trading day of the quarter), in\nsatisfaction of the aggregate of $140,500.43 of accrued interest owing on the\nNotes.\n\nAll Common Shares issued as payment for accrued interest are subject to a hold\nperiod expiring four months and one day from the date of issue of the Common\nShares.\n\nAbout Rapid Dose Therapeutics Corp.\n\nRapid Dose Therapeutics is a Canadian biotechnology company revolutionizing\ndrug delivery through innovation. The Company's flagship product QuickStrip™\nis a thin, orally dissolvable film, that can be infused with an infinite list\nof active ingredients, including nutraceuticals, pharmaceuticals and vaccines,\nthat are delivered quickly into the bloodstream, resulting in rapid onset of\nthe active ingredient. For more information about the Company, visit\nwww.rapid-dose.com.\n\nRDT Investor Contact:\nMark Upsdell, CEO\ninvestorrelations@rapid-dose.com\n416-477-1052\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:\n\nCertain information in this news release may contain forward-looking\ninformation within the meaning of applicable securities laws. Any statements\nthat are contained in this news release that are not statements of historical\nfact may be deemed to be forward-looking statements. Forward-looking\nstatements are often identified by terms such as \"intend\", \"may\", \"should\",\n\"anticipate\", \"expect\", \"potential\", \"believe\", \"intend\", \"will\", \"could\",\n\"are planned to\", \"are expected to\" or the negative of these terms and similar\nexpressions. Statements containing forward-looking information, including,\nwithout limitation, in respect of the delivery of equipment and products using\nthe QuickStrip™ product delivery method, the generation of recurring\nrevenues, the plans, estimates, forecasts, projections, expectations or\nbeliefs of RDT management as to future events or results and are believed to\nbe reasonable based on information currently available to RDT management.\nForward-looking statements necessarily involve known and unknown risks,\nincluding, without limitation, risks associated with general economic\nconditions; adverse industry events; marketing costs; loss of markets;\ntermination of WLM agreements; future legislative and regulatory developments\ninvolving cannabis; inability to access sufficient capital from internal and\nexternal sources, and/or inability to access sufficient capital on favourable\nterms; the cannabis industry in Canada generally, income tax and regulatory\nmatters; the ability to implement its business strategies; competition;\ncurrency and interest rate fluctuations and other risks. Readers are cautioned\nthat the foregoing list is not exhaustive. There can be no assurance that\nstatements of forward-looking information, although considered reasonable by\nRDT management at the time of preparation, will prove to be accurate as there\ncan be no assurance that the plans, intentions or expectations upon which they\nare based will occur. Actual results and future events could differ materially\nfrom those anticipated in such forward-looking statements. Readers should not\nplace undue reliance on forward-looking statements. Forward-looking statements\ncontained in this news release are expressly qualified by this cautionary\nstatement. The forward-looking statements contained in this news release are\nmade as of the date of this news release, and the Company expressly disclaims\nany obligation to update or alter statements containing any forward-looking\ninformation, or the factors or assumptions underlying them, whether as a\nresult of new information, future events or otherwise, except as required by\nlaw.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/304854","article_body_html":"","raw_payload":{"data":{"id":"nNFC9dSbb7","title":"Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt","author":"Newsfile Corp","ticker":"DOSE","created":"2026-07-10T23:13:31.343Z","tickers":["DOSE"],"exchange":"","article_body":"Burlington, Ontario--(Newsfile Corp. - July 10, 2026) - Rapid Dose\nTherapeutics Corp. (CSE: DOSE) (\"RDT\" or the \"Company\") announced today that\npursuant to the terms of its amended and restated secured convertible notes\ndated December 1, 2025 (the \"Notes\"), the Company issued common shares\n(\"Common Shares\") in satisfaction of the accrued interest payable on June 30,\n2026.\n\nThe Notes were issued as a result of an extension to the promissory notes that\nwere originally issued by the Company pursuant to its private placement\nfinancing (the \"Financing\") that closed in 2023. The Financing was an offering\nof units (the \"Units\") at a price of $1.00 per Unit. Each Unit consisted of\n$1.00 principal amount of Notes and five common share purchase warrants of the\nCompany (the \"Warrants\"). The Company closed all four tranches of the\nFinancing in 2023, issuing an aggregate of $3,134,445 principal amount of\nNotes and 15,672,225 Warrants.\n\nAs previously disclosed, the Company agreed with noteholders holding an\naggregate of $3,084,445 of promissory notes to extend the maturity date for\none year on their respective notes to November 30, 2026, and extend the expiry\ndate for one year on their accompanying 15,422,225 Warrants to November 30,\n2026. The Notes bear interest at 18% per annum, calculated and compounded\nmonthly, and added to principal and payable quarterly in arrears in Common\nShares at a price per share equal to the closing market price of the Common\nShares on the Canadian Securities Exchange (the \"CSE\") on the last trading day\nof each calendar quarter. The Company is permitted to prepay the Notes on 10\ndays' advance notice without notice or bonus.\n\nTherefore, in accordance with the terms of the Notes, the Company issued a\ntotal of 1,338,091 Common Shares to the holders of the Notes at a deemed issue\nprice of $0.105 per Common Share, being the closing market price of the Common\nShares on the CSE on June 30, 2026 (the last trading day of the quarter), in\nsatisfaction of the aggregate of $140,500.43 of accrued interest owing on the\nNotes.\n\nAll Common Shares issued as payment for accrued interest are subject to a hold\nperiod expiring four months and one day from the date of issue of the Common\nShares.\n\nAbout Rapid Dose Therapeutics Corp.\n\nRapid Dose Therapeutics is a Canadian biotechnology company revolutionizing\ndrug delivery through innovation. The Company's flagship product QuickStrip™\nis a thin, orally dissolvable film, that can be infused with an infinite list\nof active ingredients, including nutraceuticals, pharmaceuticals and vaccines,\nthat are delivered quickly into the bloodstream, resulting in rapid onset of\nthe active ingredient. For more information about the Company, visit\nwww.rapid-dose.com.\n\nRDT Investor Contact:\nMark Upsdell, CEO\ninvestorrelations@rapid-dose.com\n416-477-1052\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:\n\nCertain information in this news release may contain forward-looking\ninformation within the meaning of applicable securities laws. Any statements\nthat are contained in this news release that are not statements of historical\nfact may be deemed to be forward-looking statements. Forward-looking\nstatements are often identified by terms such as \"intend\", \"may\", \"should\",\n\"anticipate\", \"expect\", \"potential\", \"believe\", \"intend\", \"will\", \"could\",\n\"are planned to\", \"are expected to\" or the negative of these terms and similar\nexpressions. Statements containing forward-looking information, including,\nwithout limitation, in respect of the delivery of equipment and products using\nthe QuickStrip™ product delivery method, the generation of recurring\nrevenues, the plans, estimates, forecasts, projections, expectations or\nbeliefs of RDT management as to future events or results and are believed to\nbe reasonable based on information currently available to RDT management.\nForward-looking statements necessarily involve known and unknown risks,\nincluding, without limitation, risks associated with general economic\nconditions; adverse industry events; marketing costs; loss of markets;\ntermination of WLM agreements; future legislative and regulatory developments\ninvolving cannabis; inability to access sufficient capital from internal and\nexternal sources, and/or inability to access sufficient capital on favourable\nterms; the cannabis industry in Canada generally, income tax and regulatory\nmatters; the ability to implement its business strategies; competition;\ncurrency and interest rate fluctuations and other risks. Readers are cautioned\nthat the foregoing list is not exhaustive. There can be no assurance that\nstatements of forward-looking information, although considered reasonable by\nRDT management at the time of preparation, will prove to be accurate as there\ncan be no assurance that the plans, intentions or expectations upon which they\nare based will occur. Actual results and future events could differ materially\nfrom those anticipated in such forward-looking statements. Readers should not\nplace undue reliance on forward-looking statements. Forward-looking statements\ncontained in this news release are expressly qualified by this cautionary\nstatement. The forward-looking statements contained in this news release are\nmade as of the date of this news release, and the Company expressly disclaims\nany obligation to update or alter statements containing any forward-looking\ninformation, or the factors or assumptions underlying them, whether as a\nresult of new information, future events or otherwise, except as required by\nlaw.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/304854"},"type":"article","timestamp":"2026-07-10T23:13:31.393724406Z","server_sent_at_ms":1783725211393},"received_at":"2026-07-10T23:13:31.445Z","source_url":"https://www.newsfilecorp.com/release/304854"},"analysis":{"id":"74978","press_release_id":"85922","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["High interest rate of 18% per annum on convertible notes.","Payment of interest via common shares suggests potential cash constraints."],"eventType":"operations_update","narrative":"Rapid Dose Therapeutics issued 1,338,091 common shares to settle $140,500.43 in accrued interest on its secured convertible notes.\n\nThe shares were issued at a deemed price of $0.105, reflecting the closing market price on the Canadian Securities Exchange on June 30, 2026.\n\nThis payment satisfies the quarterly interest obligation on notes carrying an 18% annual interest rate, originally issued as part of a $3.1 million private placement in 2023.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":""},"keyFigures":{"customDimensions":{"issue_price":0.105,"shares_issued":1338091,"interest_rate_percent":18,"original_notes_principal":3134445}},"quotedText":"The Notes bear interest at 18% per annum, calculated and compounded monthly, and added to principal and payable quarterly in arrears in Common Shares","namedEntities":{"people":[{"name":"Mark Upsdell","role":"CEO"}],"products":["QuickStrip™"],"companies":[{"name":"Rapid Dose Therapeutics Corp.","ticker":"DOSE"},{"name":"Canadian Securities Exchange","ticker":"CSE","relationship":"exchange"}],"dollarAmounts":[{"amount":"$140,500.43","context":"accrued interest payable on June 30, 2026"},{"amount":"$0.105","context":"deemed issue price per Common Share"},{"amount":"$3,134,445","context":"aggregate principal amount of Notes issued in 2023"},{"amount":"$1.00","context":"price per Unit in 2023 Financing"}]},"materialImpact":{"score":3,"reasoning":"Issuing 1.34 million shares to satisfy interest payments represents direct dilution to existing shareholders. While compliant with debt terms, the high 18% interest rate and payment-in-kind nature highlight a high cost of capital and potential liquidity constraints."},"tickerRelevance":{"others":[],"primary":"DOSE"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"dilutive_interest_payment","sectorWeight":"biotech"}},"event_type":"operations_update","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":3,"narrative":"Rapid Dose Therapeutics issued 1,338,091 common shares to settle $140,500.43 in accrued interest on its secured convertible notes.\n\nThe shares were issued at a deemed price of $0.105, reflecting the closing market price on the Canadian Securities Exchange on June 30, 2026.\n\nThis payment satisfies the quarterly interest obligation on notes carrying an 18% annual interest rate, originally issued as part of a $3.1 million private placement in 2023.","key_figures":{"customDimensions":{"issue_price":0.105,"shares_issued":1338091,"interest_rate_percent":18,"original_notes_principal":3134445}},"named_entities":{"people":[{"name":"Mark Upsdell","role":"CEO"}],"products":["QuickStrip™"],"companies":[{"name":"Rapid Dose Therapeutics Corp.","ticker":"DOSE"},{"name":"Canadian Securities Exchange","ticker":"CSE","relationship":"exchange"}],"dollarAmounts":[{"amount":"$140,500.43","context":"accrued interest payable on June 30, 2026"},{"amount":"$0.105","context":"deemed issue price per Common Share"},{"amount":"$3,134,445","context":"aggregate principal amount of Notes issued in 2023"},{"amount":"$1.00","context":"price per Unit in 2023 Financing"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-10T23:15:22.665Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"micro-cap","eventGravity":"dilutive_interest_payment","sectorWeight":"biotech"}},"durationMs":111208,"modelName":"glm-4.7"}}